GlassScriptPhysician profile
John R Perkins
NPI 1437141983
$1,768.69
in general payments reported to CMS, 2019-2025
26 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $297 · 2021: $240 · 2022: $154 · 2023: $364 · 2024: $242 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $401.90 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $274.04 | 2019-2021 | |
| Amgen INC. | $183.05 | 2020-2024 | Evenity, Prolia |
| Novo Nordisk INC | $91.34 | 2020-2023 | Rybelsus, Ozempic |
| Ibsa Pharma INC. | $87.89 | 2020-2025 | Tirosint, Licart, Tirosint |
| Axsome Therapeutics, INC. | $82.39 | 2024-2025 | Symbravo, Auvelity |
| Glaxosmithkline, LLC. | $77.15 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $67.39 | 2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $67.13 | 2020-2021 | |
| Antares Pharma, INC. | $63.09 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Lilly USA, LLC | $51.06 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.44 | 2021 | |
| Halozyme INC | $30.27 | 2023 | |
| Dexcom, INC. | $27.16 | 2021-2023 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.48 | 2025 | |
| Lundbeck LLC | $19.95 | 2023 | Vyepti |
| Novartis Pharmaceuticals Corporation | $18.54 | 2019 | |
| Si-Bone, INC. | $17.13 | 2020 | |
| Exact Sciences Corporation | $17.06 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $16.05 | 2025 | Quviviq |
| Merck Sharp & Dohme LLC | $14.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2021 | |
| Abbvie INC. | $13.05 | 2021 | |
| Eisai INC. | $12.92 | 2022 | |
| Tosoh Bioscience, INC. | $10.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.